Clinical Trials
11 trialsNCT05137847 2023-12-12
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Eisai Inc.
Completed
NCT01127451 2022-04-13
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Eisai Inc.
Phase 2 Completed
NCT00211185 2020-03-18
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 2 Completed
NCT01401530 2018-11-23
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 1 Completed
NCT01432483 2015-01-26
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Eisai Inc.
No longer available
NCT00051025 2012-07-13
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
Eisai Inc.
Phase 2 Completed
NCT00211276 2012-03-14
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00055146 2009-04-17
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Eisai Inc.
Phase 2 Completed
NCT00050999 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai Inc.
Phase 4 Completed
NCT00051012 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Eisai Inc.
Phase 4 Completed
NCT00211198 2008-03-05
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Eisai Inc.
Phase 4 Completed